Mapi Pharma Group (Mapi) is an international pharmaceutical company specializing in complex bulk Active Pharmaceutical Ingredients (APIs), generic and innovative intermediates, high development barrier generics and novel finished dosage forms based on selected drug delivery systems.
Mapi is built on strong chemical and pharmaceutical R&D capabilities, deep understanding of the global market and regulatory needs and its ability to employ local cooperation and enduring relationships in all the countries it is present in. Mapi, headquartered in Israel with its R&D facilities in Israel, China and Germany, was able to secure its IP position by over 20 patents applications for APIs and formulations in less than two years of operation.
Mapi’s lead product candidate is Glatiramer Acetate Depot, a once-monthly injection for the treatment of patients with relapsing-remitting multiple sclerosis, or RRMS, in contrast to the daily 20 mg and the three-weekly 40 mg dosage of Copaxone, Teva. Branded copaxone had sales of $4.2 billion in 2015 (according to Thomson Retuers.
Mapi’s investors include: Crossroad, Jingxin Pharmaceutical and Shavit Capital.